Slideshow

Central Obesity, the Liver and Heart in the Psoriatic Patient

In this slideshow, we highlight a Brazilian study that examines the effects of biologics on the three most common psoriasis comorbidities: Metabolic syndrome, cardiovascular disease and fatty liver disease.

Psoriasis is associated with an extensive list of comorbidities ranging from erectile dysfunction to bronchial asthma. But there are three that are exponentially more common than others:  Metabolic syndrome, cardiovascular disease and fatty liver disease. In this slideshow, we highlight a Brazilian study that examines the effects of treatment with infliximab, adalimumab, etanercept and ustekinumab in psoriasis patients with these three comorbidities. 

References:

André Vicente Esteves de Carvalho, Ricardo Romiti, Cacilda da Silva Souza, et al. "Psoriasis comorbidities: complications and benefits of immunobiological treatment," Anais Brasileiros de Dermatologia. November/December 2016. http://dx.doi.org/10.1590/abd1806-4841.20165080

 

 

Related Videos
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2025 MJH Life Sciences

All rights reserved.